期刊
EUROPEAN RADIOLOGY
卷 22, 期 6, 页码 1214-1223出版社
SPRINGER
DOI: 10.1007/s00330-011-2368-z
关键词
Hepatocellular carcinoma; Chemoembolisation; TACE; Sorafenib; Liver cancer
资金
- Bayer Schering Pharma AG
Objectives To investigate the safety of transarterial chemoembolisation (TACE) in combination with sorafenib in patients with hepatocellular carcinoma (HCC). Methods Patients with Child-Pugh A/B liver function, ECOG performance status 0-2 and HCC treatable with TACE received continuous sorafenib 800 mg/day, and TACE with doxorubicin (75, 50 and 25 mg/m(2) according to serum bilirubin: < 1.5, 1.5-3, and > 3 mg/dL) and lipiodol 2 weeks after sorafenib initiation and repeated every 4 weeks. Results Fifteen patients were included (Child-Pugh A/B, = 12/3; Barcelona Clinic Liver Cancer-A/B/C, = 1/9/5; ECOG 0/2, = 14/1). Median time on sorafenib was 5.2 months (2.6-7.4 months); median number of TACE sessions was 3. Common adverse events were abdominal pain ( = 14), weight loss ( = 13), alopecia ( = 12), fatigue ( = 12) and hyperbilirubinaemia ( = 11). There were 32 serious adverse events (grade >= 3); 9/10-unscheduled hospital admissions and 4/5 deaths were considered TACE-related. The study was stopped prematurely because of safety concerns. At 6 months, 2 and 5 patients had complete or partial responses; 1 had stable disease. Median overall survival was 10.6 months (95% CI: 5.2-16 months). Conclusion These findings do not support use of an intensive, high-dose doxorubicin-based TACE regimen in combination with sorafenib in this study population. Key Points Transarterial chemoembolisation (TACE) is widely used in patients with hepatocellular carcinoma (HCC) Various antiangiogenic and other agents have been used to augment this treatment We tested lipiodol-TACE with bilirubin-adjusted doxorubicin dosing in combination with sorafenib This trial was stopped prematurely because of safety reasons Our safety results do not support the combination of sorafenib with this TACE regimen
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据